IRLAB Therapeutics AB Class A Financial Overview
IRLAB Therapeutics AB Class A's market cap is currently €15.49M. The company's EPS TTM is €-0.021720832; its P/E ratio is -1.28; IRLAB Therapeutics AB Class A is scheduled to report earnings on October 29, 2025, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.
